MXPA04004263A - Hidrazono-malonitrilos. - Google Patents

Hidrazono-malonitrilos.

Info

Publication number
MXPA04004263A
MXPA04004263A MXPA04004263A MXPA04004263A MXPA04004263A MX PA04004263 A MXPA04004263 A MX PA04004263A MX PA04004263 A MXPA04004263 A MX PA04004263A MX PA04004263 A MXPA04004263 A MX PA04004263A MX PA04004263 A MXPA04004263 A MX PA04004263A
Authority
MX
Mexico
Prior art keywords
hydrazono
malonitriles
diseases
cachexia
tumours
Prior art date
Application number
MXPA04004263A
Other languages
English (en)
Inventor
Beier Norbert
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MXPA04004263A publication Critical patent/MXPA04004263A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members

Abstract

Derivados de hidrazono-malonitrilo de la formula I(ver formula I)donde R1, R2, R3, R3Æ y R4 tienen los significados indicados en la reivindicacion 1, actuan como inhibidores de la fosfodiesterasa IV y pueden emplearse para el tratamiento de osteoporosis, tumores, caquexia, aterosclerosis, artritis reumatoidea, esclerosis multiple, diabetes mellitas, procesos inflamatorios, alergias, asma, enfermedades autoinmunes, enfermedades miocardicas y SIDA.
MXPA04004263A 2001-11-05 2002-10-10 Hidrazono-malonitrilos. MXPA04004263A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01125455 2001-11-05
PCT/EP2002/011351 WO2003039548A1 (en) 2001-11-05 2002-10-10 Hydrazono-malonitriles

Publications (1)

Publication Number Publication Date
MXPA04004263A true MXPA04004263A (es) 2004-07-08

Family

ID=8179075

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04004263A MXPA04004263A (es) 2001-11-05 2002-10-10 Hidrazono-malonitrilos.

Country Status (19)

Country Link
US (2) US7141572B2 (es)
EP (1) EP1441730B1 (es)
JP (1) JP5116940B2 (es)
KR (1) KR100898894B1 (es)
CN (1) CN1585641A (es)
AR (1) AR040629A1 (es)
AT (1) ATE335486T1 (es)
AU (1) AU2002363368B2 (es)
BR (1) BR0213683A (es)
CA (1) CA2465746C (es)
DE (1) DE60213841T2 (es)
ES (1) ES2268157T3 (es)
HU (1) HUP0401747A3 (es)
MX (1) MXPA04004263A (es)
MY (1) MY129491A (es)
PL (1) PL369738A1 (es)
RU (1) RU2302412C2 (es)
WO (1) WO2003039548A1 (es)
ZA (1) ZA200404387B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA82323C2 (uk) * 2002-08-09 2008-04-10 Меда Фарма Гмбх & Ко. Кг Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань
DE60331367D1 (de) 2002-12-30 2010-04-01 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
WO2004067006A1 (en) * 2003-01-27 2004-08-12 Pharmacia Corporation Combination of a pde iv inhibitor and a tnf-alpha antagonist
EP1612204A4 (en) * 2003-03-31 2007-04-11 Daiichi Seiyaku Co HYDRAZONE DERIVATIVE
PE20060272A1 (es) * 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
CN102614176A (zh) * 2005-04-19 2012-08-01 奈科明有限责任公司 用于治疗肺动脉高血压的罗氟司特
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
EA016264B1 (ru) 2006-03-31 2012-03-30 Янссен Фармацевтика Н.В. Бензоимидазол-2-илпиримидины и пиразины в качестве модуляторов рецептора гистамина н
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
EP2483407A2 (en) 2009-09-30 2012-08-08 President and Fellows of Harvard College Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products
WO2011163231A2 (en) * 2010-06-21 2011-12-29 Theracos, Inc. Combination therapy for the treatment of diabetes
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
CN105121439A (zh) 2013-02-19 2015-12-02 辉瑞公司 作为pde4亚型抑制剂用于治疗cns和其他病症的氮杂苯并咪唑化合物
CA2903737C (en) * 2013-03-06 2021-05-18 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor
WO2015054359A1 (en) * 2013-10-08 2015-04-16 Ebadi Mark A Methods and compositions for symptomatic reflief of the common cold
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
PE20170295A1 (es) 2014-08-06 2017-03-30 Pfizer Compuestos de imidazopiridazina
US10500178B2 (en) 2015-03-13 2019-12-10 The Board Of Trustees Of The Leland Stanford Junior University LTB4 inhibition to prevent and treat human lymphedema
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19632549A1 (de) * 1996-08-13 1998-02-19 Merck Patent Gmbh Arylalkanoylpyridazine
DE19826841A1 (de) 1998-06-16 1999-12-23 Merck Patent Gmbh Arylalkanoylpyridazine
DE19850701A1 (de) * 1998-11-04 2000-05-11 Merck Patent Gmbh Benzoylpyridazine
DE19932315A1 (de) * 1999-07-10 2001-01-11 Merck Patent Gmbh Benzoylpyridazine

Also Published As

Publication number Publication date
CA2465746C (en) 2011-09-06
EP1441730B1 (en) 2006-08-09
ATE335486T1 (de) 2006-09-15
AU2002363368B9 (en) 2003-05-19
JP2005511595A (ja) 2005-04-28
DE60213841T2 (de) 2007-02-15
AU2002363368B2 (en) 2007-12-13
KR20050035177A (ko) 2005-04-15
CA2465746A1 (en) 2003-05-15
BR0213683A (pt) 2004-10-26
CN1585641A (zh) 2005-02-23
ES2268157T3 (es) 2007-03-16
JP5116940B2 (ja) 2013-01-09
HUP0401747A3 (en) 2005-06-28
US20040261190A1 (en) 2004-12-30
EP1441730A1 (en) 2004-08-04
MY129491A (en) 2007-04-30
PL369738A1 (en) 2005-05-02
US20060270676A1 (en) 2006-11-30
US7544684B2 (en) 2009-06-09
RU2004117171A (ru) 2006-01-10
ZA200404387B (en) 2006-02-22
WO2003039548A1 (en) 2003-05-15
HUP0401747A2 (hu) 2005-01-28
AR040629A1 (es) 2005-04-13
DE60213841D1 (de) 2006-09-21
RU2302412C2 (ru) 2007-07-10
US7141572B2 (en) 2006-11-28
KR100898894B1 (ko) 2009-05-21

Similar Documents

Publication Publication Date Title
MXPA04004263A (es) Hidrazono-malonitrilos.
BR0311343A (pt) Derivados de piridazina
MY132106A (en) New pyridazin-3(2h)-one derivatives
GB0209891D0 (en) Novel compounds
RS105204A (en) Substituted 3-amino-thieno/2,3-b/pyridine- 2-carboxylic acid amide compounds and processes for preparing and their uses
WO2003093269A3 (de) Substituierte pyrazolo-pyrimidin-4-one
HK1067120A1 (en) Glutaminyl based dpiv inhibitors
JO2311B1 (en) Alkyl inhibitors Ariel phosphodiesterase-4
WO2002102313A3 (en) Pyrimidine inhibitors of phosphodiesterase (pde) 7
WO2002087513A3 (en) Fused heterocyclic inhibitors of phosphodiesterase (pde) 7
GB0305142D0 (en) Synthesis
WO2005049581A8 (en) Pyridazin-3 (2h) -one derivatives and their use as pde4 inhibitors
GB0217757D0 (en) Novel compounds
EP1864975A3 (en) Nicotinamide derivates useful as P38 inhibitors
AU3328499A (en) Phthalazinone pde iii/iv inhibitors
GEP20084329B (en) 5,7-diaminopyrazolo [4,3-d] pyrimidines useful in the treatment of hypertension
SI1075477T1 (en) Novel Benzonaphthyridine-N-oxides
MXPA03009750A (es) Compuestos quimicos.
WO2002085906A3 (en) Phthalazinones derivatives useful as pde4/7 inhibitors
AU2002358390A1 (en) Novel compounds
WO2003106450A8 (de) Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
SI1377574T1 (es)
SE9803773D0 (sv) Compounds
MXPA03001356A (es) Nuevos agentes inhibidores de beta-amiloides, procedimientos para su preparacion y su uso como medicamentos.
MXPA04001419A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson.

Legal Events

Date Code Title Description
FG Grant or registration